CROOZ
16.5.2023 05:01:27 CEST | Business Wire | Press release
CROOZ, Inc. (listed on the Tokyo Stock Exchange Standard Market: 2138; head office: Shibuya-ku, Tokyo; the President and CEO: Koji Obuchi; hereinafter "CROOZ") announced that it has officially launched PROJECT XENO, an NFT game developed by the company.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230515005017/en/
XENO_TOP (Graphic: Business Wire)
About PROJECT XENO
PROJECT XENO is a blockchain game operated by EPOCH FACTORY and developed by CROOZ, a listed Japanese company. The full-scale tactical battle NFT game combines GameFi, e-Sports, and Fun. PROJECT XENO is available globally and can be played on smartphones and PCs.
PROJECT XENO has the following features.
Feature (1) Collaboration with celebrities such as Floyd Mayweather JR
The game has appointed some ambassadors to reach users around the world; popular YouTuber Hikaru as an ambassador in Japan, along with eight-division boxing world champion Manny Pacquiao and Fumiya, "the most famous Japanese in the Philippines," as ambassadors in Southeast Asia. In addition, NFTs collaborated with former five-division boxing world champion Floyd Mayweather Jr. and others are also available.
Feature (2) Developed by a listed Japanese company
PROJECT XENO is developed and operated by a listed company that has released many hit smartphone games in the Japanese market and is able to provide high-quality games and stable operations.
Feature (3) “Web 2.5” specifications that also enable users without NFT to play
PROJECT XENO is a free-to-play game, meaning that it can still be played by users who do not own NFT. Furthermore, the game supports in-game purchases, allowing users to play the game in exactly the same way as NFT holders. The only difference with NFT holders is the presence or absence of the Earn feature. There are no discrepancies in character strength, etc., allowing PROJECT XENO to be played like any other social game. If social games are Web 2.0 and GameFi games are Web 3.0, then PROJECT XENO can be considered a Web 2.5 game.
About GXE tokens
GXE is a token distributed on PROJECT XENO. GXE is listed on MEXC Global, LBank, BKEX, Bittrex Global, and Gate.io. On May 16, 2023 (Japan time), it was also listed on BITPoint, a crypto asset exchange of the SBI Group based in Tokyo, Japan. BITPoint has been approved as a crypto asset exchange operator by the Japanese Financial Services Agency.
The latest information on PROJECT XENO
For more information on PROJECT XENO, visit the website.
Up-to-date information is also available on Twitter.
- PROJECT XENO: http://project-xeno.com/
- PROJECT XENO Official Twitter: https://twitter.com/PROJECTXENO_GLB
About CROOZ, Inc.
With the fashion shopping site "SHOPLIST.com by CROOZ" at its core, CROOZ, Inc. develops a wide range of Internet services in the entertainment domain, including shopping and games, always in step with the changing times.
https://crooz.co.jp
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230515005017/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Consulting tilføjer samarbejdsfirmaet TechSparq25.10.2026 06:09:00 CET | Pressemeddelelse
Andersen Consulting udvider sine kompetencer inden for teknologi og forretningstransformation gennem en samarbejdsaftale med TechSparq, en amerikansk virksomhed, der kombinerer strategi, commerce engineering og ai med praktisk implementering. TechSparq er et digitalt konsulenthus, der tilbyder strategi- og rådgivningstjenester, commerce engineering samt tjenester inden for ai og agentbaseret handel til virksomheder inden for detailhandel og forbrugsgoder, luksus og mode samt e-handel og direkte salg til forbrugere. Virksomheden har hovedkontor i Oregon og kombinerer strategisk planlægning med praktisk implementering for at hjælpe kunderne med at udvikle deres digitale initiativer, kundeoplevelse og driftsmodeller. "Vi etablerede vores virksomhed for at bygge bro mellem dem, der udvikler strategien, og dem, der har ansvaret for at føre den ud i livet," udtalte Dedrick Boyd, stifter af og administrerende direktør for TechSparq. "Vores samarbejde med Andersen Consulting giver os mulighed
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press release
Potential first-in-class GPC3 x 4-1BB bispecific achieves a 36% confirmed response rate at Phase 3 dose and favorable safety profile in heavily pretreated liver cancerBrain-penetrant PRMT5 inhibitor shows promising antitumor and CNS activity in the largest publicly shared MTAP-deficient datasetFirst clinical data of CEA-targeting ADC demonstrates encouraging and sustained responses in CEAhigh NSCLC BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to dise
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom